Skip to main content
  • twitter
  • facebook
  • linkedin
  • Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Close Search
Cardax, Inc. | CDXI
search
Menu
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Investor Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • search
Cardax, Inc. | CDXI

Coronavirus Disease 2019 (COVID-19)

Share Tweet Share Pin
Subscribe to Receive Updates by E-Mail Cardax News Alerts

Recent News

  • Cardax Refocuses on ZanthoSyn® Consumer Health Business August 31, 2021
  • Cardax Voluntarily Suspends SEC Reporting Obligations August 11, 2021
  • Cardax Reports Q1 2021 Results May 14, 2021

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

© 2023 Cardax, Inc. | Disclaimer and Terms of Use | Accessibility Statement

Close Menu
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Investor Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Investors
  • News
  • Subscribe
  • twitter
  • facebook
  • linkedin